The increase in price target by Morgan Stanley, while maintaining an Equal-Weight rating, suggests a cautiously optimistic outlook on Nurix Therapeutics. This adjustment reflects a positive reassessment of the company's valuation or prospects, likely leading to a short-term positive impact on the stock price as investors adjust their expectations.